Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis

Abstract

Background:

The role of tumour-infiltrating inflammation in the prognosis of patients with colorectal cancer (CRC) has not been fully evaluated. The primary objective of our meta-analysis was to determine the impact of tumour-infiltrating inflammation on survival outcomes.

Methods:

Ovid MEDLINE and EMBASE were searched to identify studies reporting the prognostic significance of tumour-infiltrating inflammation for patients with CRC. The primary outcome measures were overall survival (OS), cancer-specific survival (CS) and disease-free survival (DFS).

Results:

A total of 30 studies involving 2988 patients were identified. Studies were subdivided into those considering the associations between CRC survival and generalised tumour inflammatory infiltrate ( n=12) and T lymphocyte subsets ( n=18). Pooled analyses revealed that high generalised tumour inflammatory infiltrate was associated with good OS (HR, 0.59; 95% CI, 0.48–0.72), CS (HR, 0.40; 95% CI, 0.27–0.61) and DFS (HR, 0.72; 95% CI, 0.57–0.91). Stratification by location and T lymphocyte subset indicated that in the tumour centre, CD3 ⁺, CD8 ⁺ and FoxP3 ⁺ infiltrates were not statistically significant prognostic markers for OS or CS. In the tumour stroma, high CD8 ⁺, but not CD3 ⁺ or FoxP3 ⁺ cell infiltrates indicated increased OS. Furthermore, high CD3 ⁺ cell infiltrate was detected at the invasive tumour margin in patients with good OS and DFS; and high CCR7 ⁺ infiltrate was also indicated increased OS.

Conclusion:

Overall, high generalised tumour inflammatory infiltrate could be a good prognostic marker for CRC. However, significant heterogeneity and an insufficient number of studies underscore the need for further prospective studies on subsets of T lymphocytes to increase the robustness of the analyses.